small molecule

PHOSLYRA

CALCIUM ACETATE

Loss of exclusivityFebruary 2030latest FDA-listed patent expiry
CompanyFRESENIUS MEDICAL CARE RENAL THERAPIES GROUP LLC

Drug detail

Brand namePHOSLYRA
Active ingredientCALCIUM ACETATE
Strength667MG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
8591938February 2030product
8592480July 2027use U-1469
9089528July 2027use U-1469

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

PHOSLYRA patent cliff — loss of exclusivity February 2030 | CliffBio